While many tumors are initially responsive to RT, ADT, and ARSIs, around 20–30% of patients will progress within 2–3 years and eventually transition to a more aggressive, AR-independent form of PCa known as castration-resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC), both of which are incurable and often lethal within 2 years [16,17]. Here, AR is linked to posterior cortical atrophy.